The FDA has accepted for review a new drug application seeking the approval of rivoceranib in combination with camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma (HCC).
Please refer to the following website for further details: www.elevartherapeutics.com
Targeted Oncology
FDA Accepts NDA for Rivoceranib Plus Camrelizumab in Unresectable HCC (onclive.com)
Drugs.com
"Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma"
PharmiWeb
"Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma"
The Korea Times
"HLB's liver cancer treatment Rivoceranib closer to FDA approval"